A proopiomelanocortin-derived peptide sequence enhances plasma stability of peptide drugs.

Bioactive peptide drugs hold promise for therapeutic application due to their high potency and selectivity but display short plasma half-life. Examination of selected naturally occurring peptide hormones derived from proteolytic cleavage of the proopiomelanocortin (POMC) precursor lead to the identification of significant plasma-stabilizing properties of a 12-amino acid serine-rich orphan sequence NSSSSGSSGAGQ in human gamma 3-melanocyte-stimulating hormone (MSH) that is homologous to previously discovered NS(n)GGH (n = 4-24) sequences in owls. Notably, transfer of this sequence to des-acetyl-alpha-MSH and the therapeutically relevant peptide hormones neurotensin and glucagon-like peptide-1 likewise enhance their plasma stability without affecting receptor signaling. The stabilizing effect of the sequence module is independent of plasma components, suggesting a direct effect incis. This natural sequence module may provide a possible strategy to enhance plasma stability, complementing existing methods of chemical modification.